Ronald M. Benoit, Jr., MD, presented “Cesium-131 Prostate Brachytherapy: A Single Institutional Long-Term Experience” for the Grand Rounds in Urology audience in May, 2020.
How to cite: Benoit Jr., Ronald M. “Cesium-131 Prostate Brachytherapy: A Single Institutional Long-Term Experience” May, 2020. Accessed Jun 2020. https://grandroundsinurology.com/cesium-131-prostate-brachytherapy-a-single-institutional-long-term-experience/
Cesium-131 Prostate Brachytherapy: A Single Institutional Long-Term Experience – Summary:
Ronald M. Benoit Jr., MD, Associate Professor, Clinical Vice Chair of Urology, Director of General Urology, and Chief of the Division of Community Urology at the University of Pittsburgh School of Medicine, describes the long-term results of a single institution cohort study investigating brachytherapy using Cesium-131 (Cs-131) in 669 prostate cancer patients. He goes on to describe the long-term impact on urinary function caused by using iodine and palladium implants, how study results using Cs-131 demonstrated shorter duration of urinary morbidity, and the relative 5- and 10-year biochemical-free recurrence rate among patients stratified at low, intermediate, and high risk levels.